Literature DB >> 32484808

RpoS is a pleiotropic regulator of motility, biofilm formation, exoenzymes, siderophore and prodigiosin production, and trade-off during prolonged stationary phase in Serratia marcescens.

Han Qin1, Ying Liu1, Xiyue Cao1, Jia Jiang1, Weishao Lian1, Dairong Qiao1, Hui Xu1, Yi Cao1.   

Abstract

Prodigiosin is an important secondary metabolite produced by Serratia marcescens. It can help strains resist stresses from other microorganisms and environmental factors to achieve self-preservation. Prodigiosin is also a promising secondary metabolite due to its pharmacological characteristics. However, pigmentless S. marcescens mutants always emerge after prolonged starvation, which might be a way for the bacteria to adapt to starvation conditions, but it could be a major problem in the industrial application of S. marcescens. To identify the molecular mechanisms of loss of prodigiosin production, two mutants were isolated after 16 days of prolonged incubation of wild-type (WT) S. marcescens 1912768R; one mutant (named 1912768WR) exhibited reduced production of prodigiosin, and a second mutant (named 1912768W) was totally defective. Comparative genomic analysis revealed that the two mutants had either mutations or deletions in rpoS. Knockout of rpoS in S. marcescens 1912768R had pleiotropic effects. Complementation of rpoS in the ΔrpoS mutant further confirmed that RpoS was a positive regulator of prodigiosin production and that its regulatory role in prodigiosin biosynthesis was opposite that in Serratia sp. ATCC 39006, which had a different type of pig cluster; further, rpoS from Serratia sp. ATCC 39006 and other strains complemented the prodigiosin defect of the ΔrpoS mutant, suggesting that the pig promoters are more important than the genes in the regulation of prodigiosin production. Deletion of rpoS strongly impaired the resistance of S. marcescens to stresses but increased membrane permeability for nutritional competence; competition assays in rich and minimum media showed that the ΔrpoS mutant outcompeted its isogenic WT strain. All these data support the idea that RpoS is pleiotropic and that the loss of prodigiosin biosynthesis in S. marcescens 1912768R during prolonged incubation is due to a mutation in rpoS, which appears to be a self-preservation and nutritional competence (SPANC) trade-off.

Entities:  

Year:  2020        PMID: 32484808     DOI: 10.1371/journal.pone.0232549

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  5 in total

Review 1.  Flagellotropic Bacteriophages: Opportunities and Challenges for Antimicrobial Applications.

Authors:  Nathaniel C Esteves; Birgit E Scharf
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

2.  PsrA is a novel regulator contributes to antibiotic synthesis, bacterial virulence, cell motility and extracellular polysaccharides production in Serratia marcescens.

Authors:  Xuewei Pan; Mi Tang; Jiajia You; Tolbert Osire; Changhao Sun; Weilai Fu; Ganfeng Yi; Taowei Yang; Shang-Tian Yang; Zhiming Rao
Journal:  Nucleic Acids Res       Date:  2022-01-11       Impact factor: 16.971

3.  Improving prodigiosin production by transcription factor engineering and promoter engineering in Serratia marcescens.

Authors:  Xuewei Pan; Jiajia You; Mi Tang; Xian Zhang; Meijuan Xu; Taowei Yang; Zhiming Rao
Journal:  Front Microbiol       Date:  2022-08-03       Impact factor: 6.064

4.  RpoS Activates the Prodigionsin Production by Activating the Transcription of the RpoS-Dependent Pig Gene Cluster in Serratia marcescens FS14.

Authors:  Baoling Yang; Fenglian Chu; Haixia Li; Weiwu Wang; Tingting Ran; Dongqing Xu
Journal:  Indian J Microbiol       Date:  2021-06-08

5.  Antibiotics Used in Empiric Treatment of Ocular Infections Trigger the Bacterial Rcs Stress Response System Independent of Antibiotic Susceptibility.

Authors:  Nathaniel S Harshaw; Nicholas A Stella; Kara M Lehner; Eric G Romanowski; Regis P Kowalski; Robert M Q Shanks
Journal:  Antibiotics (Basel)       Date:  2021-08-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.